Fig. 4

Proportions of Patients Achieving ACR Response Criteria Through 5 Years (AO). ACR20/50/70, ≥ 20%/50%/70% improvement in American College of Rheumatology response criteria; AO, as observed; mono, monotherapy; MTX, methotrexate; QD, once daily; UPA, upadacitinib. ^aPatients in the UPA 30 mg treatment group were later switched to the approved UPA 15 mg dose per protocol amendment. The switch occurred at different visits across the patient population, with the earliest switch occurring at the week 108 visit